Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Monitoring of Donor-specific Antibodies (DSA) After Combined Treatment With Immunoglobulin A and Immunoglobulin M-enriched Intravenous Human Immunoglobulins and Plasmapheresis and Rituximab in Lung Transplantation

NCT03798860 is registered in ClinicalTrials.gov with Hannover Medical School as lead sponsor.

NCT NCT03798860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03798860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Monitoring of Donor-specific Antibodies (DSA) After Combined Treatment With Immunoglobulin A and Immunoglobulin M-enriched Intravenous Human Immunoglobulins and Plasmapheresis and Rituximab in Lung Transplantation
Lead sponsor
Hannover Medical School
Phase
Observational
Overall status
Completed
Start date
October 1, 2018
Completion date
December 31, 2025
Enrollment
340 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

donor-specific anti-human leukocyte antigen(hla) antibodies, lung transplantation